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1. Introduction
Brucellosis is an infectious zoonotic disease of 
domestic animals, as well as humans, globally [1–3]. 
Various domestic animals such as camels, goats, sheep, 
cows as well as humans are affected by brucellosis. 
It is caused by the Brucella species such as Brucella 
melitensis in small ruminants, Brucella abortus in cat-
tle, and Brucella canis in dogs [4–5] Brucella species are 
Gram-negative, small coccobacillus, slow-growing and 
intracellular bacteria that are capable of surviving and 
multiplying within macrophages, dendritic cells, pla-
cen tal trophoblasts, and epithelial cells. Brucella species 
can survive under extreme conditions of temperature, 
humidity, pH, and persist in frozen and aborted materi-
als for longer durations [6]. 
Although several countries are affected by brucello-
sis, it is still a neglected disease and no official program 
for surveillance and eradication of animal brucellosis 
has been proposed [7]. In many developing countries 
of Africa, Asia, Central, and South America, clinical 
disease is recorded among different animals [8, 9]. The 
impact of brucellosis on human health is a major issue 
[10]. In humans, it causes fever, nausea, muscular pain, 
abdominal pain, sweating, weakness, decreased appe-
tite, weight loss, and liver inflammation [11]. This dis-
ease in domestic animals poses a threat to free animal 
movement and trade of animals and various animal 
products and causes huge economic losses. It also leads 
to economic burden due to decreased milk production, 
breeding failure, and abortion in the domestic animals 
infected with Brucella spp. [12].
The development of DNA markers and molecular 
biology techniques are important tools for genomics-
based studies in animal biotechnology [13]. It has led 
to genetic improvement and markers now help in the 
selection of best quality breeds of animals. Over the 
last 20 years, DNA markers have resulted in tremen-
dous genetic improvement in farm animals. Recent 
developments in molecular biology techniques have 
revealed genetic polymorphisms in DNA sequences, 
which have been used extensively as markers for assess-
ing the genetic basis of the phenotypic variations in 
animals. The genetic markers indicative of changes at 
the DNA level are called molecular markers [14]. The 
PCR has become an important tool for molecular DNA 
studies, including the detection of DNA polymorphism 
(fingerprinting), analysis of genotyping, and genome 
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mapping. Along with microbial techniques, 16S rRNA 
gene sequencing and RAPD methods are very essen-
tial in molecular diagnosis. Using an array of random 
single RAPD primers, it is possible to determine the 
polymorphism that can be used in DNA analysis [15].
Improvement of the livestock industry and the use 
of improved prevention measures to control brucellosis, 
require an understanding of the disease risk and the 
prevalence of infection in the human population and 
animal hosts. Epidemiological studies of brucellosis in 
humans as well as domestic animals globally is urgently 
needed to effectively control this disease [16–21]. The 
objective of this work are to describes the current sta-
tus of brucellosis and the risk factors of the disease in 
animals and the human population. In addition, there 
is a further discussion of the various issues related to 
the control and prevention of brucellosis in domestic 
animals and humans.
2. Historical background of Brucellosis
The disease brucellosis has existed since time imme-
morial. The analysis of the skeleton of Australopithecus 
africanus from the late Pliocene era revealed the effect of 
brucellosis in human ancestors [15]. Furthermore, DNA 
analysis and pathological findings from human skeletal 
remains and buried cheese remains indicated the pres-
ence of brucellosis in some countries in the Middle East 
and Europe in 79 A. D. [15, 16]. The earliest record of this 
disease was in 1859, and it mentioned that animal abor-
tions were most probably due to brucellosis [1]. How- 
ever, in the 1880s, the causative agent of this disease, Bru- 
cella melitensis, was isolated and identified. The term 
brucellosis was named after Sir David Bruce who isola-
ted and characterized the infectious agent from a soldier 
in Malta in 1886. This disease was responsible for inflict-
ing severe mortality and morbidity in British military 
personnel in Malta and hence was also well-known as 
Malta or Mediterranean fever [6]. It was also known 
as Bang’s disease after the isolation of the causative agent 
Brucella abortus in 1897 by Danish veterinarian Bern-
hard Bang. Due to the “wave-like” characteristic of the 
fever, which rises and falls over several weeks in patients, 
it is also known as “undulant fever”. Other names for 
brucellosis include Gibraltar fever, Rock fever, Cyprus 
fever, and typhomalarial fever in humans and animals.
3. Prevalence of brucellosis 
Although Brucellosis has been very well controlled 
in many developed countries, it is still a major concern 
in Asia including Middle Eastern countries, Africa, 
Mediterranean countries and South America. Human 
brucellosis has re-emerged in China since 1990, due to 
the drastic growth of animal husbandry which increases 
the probability of human infection [3]. Brucellosis is 
still a major concern in the Indian subcontinent. India 
has one of the largest bovine populations in the world, 
which is responsible for the continued exposure of 
workers in milk industry to these animals and hence 
there are high incidences of brucellosis in humans [17]. 
A seroprevalence study in India indicated brucellosis 
seroprevalence ranging from 2% to 18% in suspected 
patients [17]. Several countries which were endemic 
such as Malta, France, Ireland, Israel have been success-
ful in eradicating the disease. Studies in various coun-
tries, have indicated that B. melitensis is the main cause 
of human brucellosis, while infection with B. abortus is 
less frequent [22]. Domestic animals are a natural reser-
voir of Brucella spp. and animal-to-human transmission 
occurs through the consumption of infected meat and 
milk. Serological data for the prevalence of brucellosis 
in various provinces in Saudi Arabia is still not available 
[22, 23]. The incidence of the disease had been reported 
from the Northern, Southern, and Central regions of 
Saudi Arabia [24, 25]. A seroprevalence study by Ageely 
and colleagues in the Jazan province of Saudi Arabia 
revealed that the prevalence of human brucellosis was 
higher in patients ≥ 40 years old (20 %) as compared 
to the population < 40 years (12 %). Seroprevalence 
was higher in the rural population (39.3%) than in the 
urban population (4.6%), and significantly higher in 
the Saudi population (14.5%) compared to the non-
Saudi population (3.0%). However, the prevalence was 
much higher in males (16.4%) than females (7.1%) [16]. 
Brucella spp. infection in humans is mainly through the 
consumption of raw milk and meat products derived 
from infected goats or camels. It has also been observed 
that laboratory workers, hospital staff, and veterinar-
ians are more prone to brucellosis [23, 26, 27]. Brucel-
losis is caused by bacteria belonging to genus Brucella 
in humans and several other animals, including goat, 
cows, buffaloes, sheep, pigs, camels and reindeer [1, 28]. 
4. Taxonomy
Brucella spp. are Gram-negative cocci or small rods, 
non-motile, non-encapsulated, non-flagellated, non-
spore forming aerobic microbes. It has the capability 
to invade, epithelial cells, macrophages, dendritic cells 
and placental trophoblasts [7]. 
Genus Brucella belongs to the alpha-2 subdivi-
sion of class Proteobacteria and 10 different species 
of Brucella based on the host specificity that has been 
reported. These species are B. melitensis (goats), B. abor-
tus (cattle), B. ovis (sheep), B. canis (dogs), B. neoto-
mae (desert woodrats), B. suis (swine), B. pinnipedia 
(seal), B. microti (voles), B. cetacea (cetacean), and 
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B. inopinata (unknown) [29]. Among the known 
10  species of Brucella only B. melitensis, B. abortus, 
B. canis and B. suis, have been found to cause infection 
in humans. B. ovis and B. neotomae are not pathogenic 
to humans. Most of the human infection cases glob-
ally are caused by B. melitensis [30]. B. melitensis and 
B. suis are more infectious and virulent in humans com-
pared to B. canis or B. abortus [31]. B. melitensis, B. suis 
and B. abortus are known to have 3, 5, and 7 subtypes, 
respectively [32, 33]. Sequencing the genome of Bru-
cella species revealed a  sequence homology of more 
than 99% among the species [29, 34].
Most Brucella species possess smooth lipopolysac-
charide (SLPS) in the outer cell wall, while B. canis 
and B. ovis have rough lipopolysaccharide (RLPS) and 
protein antigens [35]. SLPS contains an immunogenic 
O-polysaccharide, defined as a homopolymer of 4, 
6-dideoxy-4-formamide-α-D mannose, which is con-
nected by glycosidic linkages. Brucella species that pos-
sess smooth lipopolysaccharide, particularly B. meliten-
sis, are known to undergo dramatic structural variations 
during growth, and more often change to rough form 
(R) and occasionally to mucoid form (M). During the 
change in morphology to rough form (R), bacterial 
colonies appear to be less transparent, with a  more 
granular surface. During the change in morphology 
to mucoid form (M), the bacterial cells appear to have 
a gelatinous texture and their color changes from white 
to brown in reflected light. An intermediate form (I) 
has also been observed during the change in morpho-
logy from smooth (S) to rough form (R). It had been 
shown that changes in the bacterial cell morphology are 
associated with marked differences in virulence, patho-
genicity and serological properties of Brucella spp. [36].
5. Epidemiology of Brucellosis
The epidemiology of brucellosis has dramatically 
changed over the past few years due to improvement 
in hygiene, socio-economic conditions and an increase 
in international travel. Incidence of human brucellosis 
has been reported for the first time from the regions 
of central Asia and in some countries. Particularly in 
Middle East countries, there is a drastic increase in the 
incidences of brucellosis in humans [30]. 
Brucellosis affects domestic as well as wild animals. 
It has been reported to occur worldwide wherever 
animals are raised [37]. Although some industrial-
ized countries in Europe and America have been able 
to eradicate brucellosis in domestic animals through 
intensive control schemes, the disease is still a severe 
problem in several developing countries [38].
B. melitensis is the most pathogenic species and 
comprises three biovars. Biovars 1 and 3 have been 
detected most often in domestic animals in the Middle- 
East, Mediterranean and Latin American countries [39, 
40]. Brucellosis is considered a major barrier to the free 
trade of domestic animals and various animal products 
and is responsible for significant economic losses due 
to abortion in domestic animals [41].
6. Risk factors for brucellosis
Various factors such as environmental factors and 
the host biology can affect the occurrence and preva-
lence of brucellosis. Some of these factors include the 
age of the animals, herd size, sanitary conditions of ani-
mal farms and climatic conditions [24, 42] It has also 
been observed that sexually mature animals are more 
prone to the infection and bacteria mainly localize in 
the reproductive organs, particularly in pregnant ani-
mals. Besides, Brucella spp. may also be localized in the 
mammary glands [43].
Many people in poor African countries such as 
Ethiopia are dependent on livestock for their livelihood 
which leads to their close association with the domestic 
animals, increasing the risk of infection through Bru-
cella spp. [42, 44]. Cases of brucellosis are very high 
in rural areas as farmers live closely with their domes-
tic animals and more often consume unpasteurized 
milk products [24]. In countries like Ethiopia, the habit 
of consuming raw milk, improper handling of an 
aborted fetus and reproductive excretions are respon-
sible for the transmission of zoonotic diseases like bru-
cellosis to humans [45]. 
In many other countries, risk factors for infection 
with Brucella include consumption of contaminated 
animal products such as milk and meat, handling of 
infected animals, traveling to an endemic area and 
mishandling cultures of Brucella sp. in laboratories 
and diagnostic centers. Veterinarians, dairy workers, and 
slaughterhouse workers are more susceptible to infec-
tion with Brucella [8]. Recent studies showed a  poor 
community’s knowledge of brucellosis and the risk asso-
ciated with brucellosis among people living adjacent to 
Awash National Park in Ethiopia [46]. Hence, there is 
an utmost need to create awareness about the disease, 
improve knowledge, attitudes and practices among live-
stock owners, which would further lead to a significant 
reduction in the transmission of the bacteria from ani-
mals to humans in the disease-prone areas [41].
7. Transmission
Brucella melitensis has been found to be sexually 
transmitted in sheep and goats. The transmission of 
brucellosis is facilitated by the intermingling of animal 
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herds that belong to different owners and by the pro-
curement of cattle from sources that are not properly 
screened for the disease [2]. Moreover, using common 
male breeding stock also increases the risk of disease 
transmission among domestic animals. Other factors 
that can promote the transfer of infection include the 
intermingling of animals during grazing, the crowd-
ing of animals in farms, marketplaces or animal fairs 
[1]. Following an abortion in domestic animals, animal 
farms can become contaminated with Brucella spp. and 
other animals on the farm may acquire the disease by 
ingestion, inhalation, skin contamination or udder inoc-
ulation. Sometimes, pooled colostrums used for feeding 
newborns can also play a role in the transmission of 
the disease. Artificial insemination may also promote 
the transmission of the Brucella spp. to healthy animals. 
In humans, brucellosis is caused by B. melitensis, 
B. abortus and B. suis which are transmitted by an 
infected goat, pigs, sheep or cows to healthy humans 
[47]. Besides, domestic and wild animals are also 
infected with Brucella sp. and can act as reservoirs of 
bacteria that can be transmitted to both humans and 
domestic animals [41]. Exposure of humans to infected 
domestic animals or the consumption of milk or meat 
products derived from infected animals enhances the 
risk of acquiring brucellosis [8]. The transmission of 
brucellosis may also occur through blood transfusion 
or organ transplantation. Some people such as farmers, 
farm laborers, animal attendants, shepherds, and veteri-
narians are at a very high risk of acquiring the infection. 
These workers are always at a very high risk of infection 
with Brucella spp. due to direct contact with infected 
animals or constant exposure to the contaminated envi-
ronments. The main source of Brucella infection in the 
urban population is usually contaminated food, milk or 
dairy products derived from infected animals [20, 47].
8. Clinical Symptoms
Animals
The incubation period in brucellosis is found to be 
highly variable and is defined as the period between the 
exposure and first appearance of clinical symptoms or 
abortion. In cows, infected at the early stage of preg-
nancy, abortion may occur after 225 days. But for those 
infected at seven months gestation, abortion may occur 
after 50 days. Various factors such as age, sex, stage of 
gestation, infective dose and immune system of the 
animals may influence the incubation period [2, 48]. 
In very susceptible animals with weak immune sys-
tems, abortion occurs during the third trimester and 
other clinical symptoms include metritis, retained pla-
centa, and reduced milk production [49]. It has been 
observed that abortion may occur in 80% of animals 
that are infected with B. abortus [48]. Brucellosis is one 
of the major causes of infertility in camels, cows, goats, 
sheep, pigs, and dogs [50, 51]. Infection in male animals 
causes hygromas, orchitis, and inflammation of the 
seminal vesicles [50]. 
9. Human brucellosis
In humans, there are three stages of brucellosis i.e. 
acute, subacute or chronic phase and the incubation 
period is two to three weeks and sometimes several 
months. The predominant symptoms of brucellosis in 
humans include intermittent fever, headache, backache, 
weakness, weight loss, anorexia and mental depression 
[52, 53]. During the chronic phase, knee joints are also 
affected [54]. Complications may occur in the gastro-
intestinal, cardiovascular, pulmonary, lymphatic, and 
nervous systems [55, 56]. The effect of Brucella infec-
tion on the nervous system causes neuro-brucellosis, 
which is characterized by fever, headache, psychosis, 
seizures, behavioral changes, and spastic paresis [57].
10. Diagnosis of brucellosis
It has always been difficult to clinically diagnose 
brucellosis in animals as well as in humans [13]. Pres-
ently, the serological method, culture-based method, 
and molecular techniques are employed to detect Bru-
cella infection in animals and humans [58]. Diagnostic 
tests are based on the detection of the causative agent 
Brucella sp., the detection of antibodies in the serum 
and allergic reactions [59].
11. Detection of Brucella organisms
Culture 
Culture-based methods are employed to detect Bru-
cella spp. in milk, blood or colostrum, including fetal 
membranes, uterine discharges of infected animals and 
aborted fetuses. The supra mammary lymph nodes or 
retropharyngeal or prescapular lymph nodes are also 
very suitable samples for the diagnosis of brucello-
sis in animals [48, 60]. For the diagnosis of brucellosis 
in humans, blood, urine and cerebrospinal fluid are 
screened in order to detect the bacteria, particularly 
during the acute stage of brucellosis [12, 14, 61]. How-
ever, culture-based methods are not suitable for the 
diagnosis of brucellosis during the chronic phase, as the 
bacterial count is very low. Another major drawback of 
the culture-based methods is the slow growth rate of the 
Brucella species. Moreover, there is a very high risk to 
the health of the laboratory personnel [1, 12, 13].
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Microscopic examination
Staining methods such as Ziehl Nelsen staining 
can also be used to detect Brucella in infected ani- 
mals. However, this staining technique is not very spe-
cific to Brucella spp., as other microorganisms such as 
Chlamydia, Coxiella, and Nocardia exhibit acid-fast 
features [47].
12. Serological tests
Several serological tests are currently being 
employed for qualitative and quantitative detection of 
specific immunoglobulins of Brucella organism-spe-
cific antibody titer in the infected animals. Serological 
tests such as Rose Bengal Plate test (RBPT), Comple-
ment Fixation Test (CFT), Serum Agglutination Test 
(SAT), and Enzyme-Linked Immunosorbent Assay 
(ELISA) are routinely used for diagnosis of brucello-
sis in animals and human [60]. Milk Ring Test (MRT) 
is employed for the detection of Brucella organisms in 
infected animals [62].
Serum Agglutination Test (SAT)
Globally, this test has been used for the detection of 
brucellosis in infected animals and humans for decades 
[63]. However, there are some drawbacks associated 
with this technique, which limit its utility. This test is 
unable to distinguish natural Brucella infections from 
the vaccination effect. It is also unable to detect Brucella-
specific antibodies after abortion in infected animals 
and during the chronic phase of brucellosis [48, 50].
Rose Bengal Plate test (RBPT)
Rose Bengal test is usually used for the diagnosis 
of brucellosis in most countries. It has been effectively 
used for screening domestic animals, wildlife and the 
human population [64]. The probability of obtaining 
false-negative data is very rare. However, there is a pos-
sibility of getting false-negative results during the early 
stages of infection, whereas false-positive results can 
occur due to vaccination and cross-reactivity [48].
Milk Ring Test (MRT)
This test is used for the screening of domestic ani-
mals to detect brucellosis infection [48]. However, the 
major limitation of this test is its very low sensitivity 
compared to other techniques such as ELISA [65]. The 
comparison of the MRT and ELISA techniques by test-
ing milk and sera, respectively, obtained from the same 
female animals indicate that the ELISA test revealed 
more positive animals as compared to MRT [59]. Low 
sensitivity of the Milk ring test is attributed to mastitis, 
vaccination with S19, temperature variations and the 
use of soured milk in the test [48]. 
Complement Fixation Test (CFT)
The major advantage of the complement fixation 
test is its high specificity and sensitivity and it is a com-
monly used test for serological detection of brucellosis 
infection in domestic animals and humans [66]. Non-
specific reactions are not an issue in the Complement 
Fixation Test. Moreover, unlike the Serum agglutination 
test, the CFT is more suitable for screening brucellosis 
infection during the chronic stage of the disease.
Enzyme Linked – Immunosorbent Assay (ELISA)
The diagnosis of Brucella infection has improved 
through the development of ELISA technology [55, 
65]. Among various ELISA methods, the Competitive 
ELISA (c-ELISA) is more robust, very sensitive, and 
highly specific. The c-ELISA has the capability to differ-
entiate naturally infected animals from the vaccinated 
ones and also has the ability to rule out animals infected 
with cross-reacting microorganisms. The c-ELISA can 
be performed by using the serum as well as milk sam-
ples from different animal species without compromis-
ing the sensitivity and specificity [64, 67].
13. Molecular diagnostic methods
Currently, molecular biology techniques are being 
used extensively to identify the causative agents, as 
these techniques are less time-consuming, have high 
specificity and sensitivity to detect microorganisms [60, 
68]. In addition, restriction endonuclease and hybri-
dization have been used extensively for decades for 
Brucella detection [14, 69]. 
PCR is very sensitive, highly specific, rapid, and eas-
ily amenable for high-throughput screening. It is also 
more suitable for the detection of slow-growing bacteria 
such as Brucella [70]. Due to its very high sensitivity, 
the PCR based method has the capability to detect tiny 
amounts of bacteria in clinical samples. It has also been 
demonstrated that the PCR technique is able to detect 
dead microbes in clinical samples, hence reducing the 
need for proper sample preservation before analysis 
[71]. This method of detecting Brucella infection is 
highly reproducible and very reliable, however, care 
should be taken to avoid contamination during analysis 
in the laboratory [72].
PCR-based protocols for the detection of Brucella 
spp. in clinical samples have been designed and devel-
oped. These methods are based on the amplification of 
gene BCSP31 which is highly conserved among Brucella 
spp., or the amplification of the 16S rRNA gene [72]. 
This approach is useful for screening when biovar or 
species designation is not critical. In order to distinguish 
Brucella species or biovar, PCR protocols have been 
developed based on gene loci, which vary among biovars 
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and species. However, such gene targets are not com-
mon in Brucella, as the genus is unusually homogeneous 
and conserved. While few deletions and rearrangements 
have been found within a biovar or species, most of the 
differences at genetic levels consist of single nucleotide 
polymorphisms [69]. Differential PCR based methods 
are of great value for epidemiological studies, disease 
monitoring, and species-specific eradication program. 
The differential PCR protocols can be denoted as spe-
cies-specific and genus specific. In the case of species-
specific methods, three approaches have been reported 
(i) protocols designed with highly specific primers and 
stringent assay conditions; (ii) protocols developed with 
low-specific primers and less stringent PCR conditions, 
and (iii) protocols designed with random primers under 
very flexible assay conditions [73, 77].
14. Control and prevention of brucellosis 
Brucellosis is an infectious disease that has been 
controlled and eradicated in some countries in the 
world [3]. In sub-Saharan Africa, animal health ser-
vices have been substantially deteriorated over the last 
20 years due to various factors such as reduction in 
government budgets, especially the funds required 
to control brucellosis [81] Hence, various programs 
that require the use of disease prevention measures, 
information exchange, and coordinated surveillance, 
are not properly implemented in many sub-Saharan 
countries [2, 18, 42, 82]. 
The primary objectives for the control and preven-
tion of brucellosis are centered on the economic impacts 
of the disease and its public health consequences [73]. 
Control activities mainly reported by countries include 
surveillance, controlling the movement of domestic 
animals, treatment of meat and milk products and 
animal vaccination, [3, 42, 84]. In Mozambique, the 
control of brucellosis was well organized by using the 
S19 vaccine in cattle until 1980. A strain 19 vaccine 
produced by the Underreport Veterinary Institute in 
South Africa containing viable Brucella cells was used. 
The vaccine was administered subcutaneously to heifer 
calves at four to eight months of age. However, recently 
some private farmers have been using S19 vaccina-
tion in adult cows. Also, surveillance and movement 
control were also implemented at a  very low level, 
resulting in a drastic increase in cases of brucellosis. 
Brucella abortus vaccine, strain RB-51, live culture, 
licensed in 1996, has been extensively used in USA to 
eradicate brucellosis [73–77].
Antibodies against Brucella cell wall O-polysaccha-
ride (OPS) component of smooth lipopolysaccharide is 
known to confer protective efficacy to the currently used 
vaccines. However, the detection of these antibodies is 
also used in diagnosis of brucellosis in animals, and so 
it becomes very difficult to differentiate vaccinated ani-
mals from infected animals and this hampers the effort 
to control the disease [75]. In order to sort out this issue, 
it has been proposed that combining anti-Brucella OPS 
antibody response with the induction of cell-mediated 
response would provide highly effective protection 
against brucellosis which can be achieved by the con-
jugation of O-polysaccharide (OPS) to a highly immu-
nogenic Brucella protein. Such type of glycoconjugate 
vaccine would be more effective in protecting animals 
and humans against brucellosis and would not interfere 
with the diagnostic testing for Brucella infection [75].
Acknowledgments
This work was supported by the King Abdul Aziz City for 
Science and Technology in the Kingdom of Saudi Arabia, Grant 
No. (1-18-01-009-0009). The authors also acknowledge assistance 
from the Science and Technology Unit, Deanship of Scientific 
Research and Deanship of Graduate Studies and acknowledge assis-
tance from the Dept. of Biological Sciences, Faculty of Science, King 
Abdul Aziz University (KAU), Jeddah, KSA.
References
 1. Corbel M.J.: Brucellosis: an overview. Emerg. Infect. Dis. 3, 
213–221 (1997)
 2. Wang W., Lu X., Li C., Ri M.J., Cui W.: A man with recurrent 
fever, arthritis, and rashes-brucellosis. A case reports. BMC Inf. 
Dis. 20, 1–4 (2020)
 3. Shi Y., Gao H., et al.: Clinical features of 2041 human brucellosis 
cases in China. PLoS One, 13, e020550 (2018)
 4. Zheng R., Xie S., et al.: A systematic review and meta-analysis of 
epidemiology and clinical manifestations of human brucellosis 
in China. Biomed. Res. Int. 5712920 (2018)
 5. Crawford R.P., Huber J.D., Adams B.S. (1990). Epidemiology 
and Surveillance. In: Animal brucellosis. Edited by Nielsen, 
K and Duncan, lR. Boca Raton, Florida. CRe Press. pp. 131–151.
 6. Corbel M.J., Beeching N.J.: Brucellosis, Chapter 141. Pp. 914–917. 
In: Harrison’s textbook of Internal Medicine, 16th ed.; McGraw-
Hill, New York. (2004)
 7. Ghorbani A., Rabbani K.M., Zarkesh-Esfahani H., Shari-
fiyazd I.H., Dehghan K.A, Emami H.: Comparison of serology, 
culture, and PCR for detection of brucellosis in slaughtered 
camels in Iran. Comp. Clin. Path. 22, 913–917 (2013)
 8. Khamesipour F., Doosti A., Taheri H.: Molecular detection of 
Brucella spp. in the semen, testis and blood samples of cattle and 
sheep. J. Pure Appl. Micr. 7 (Suppl. Edn.) 495–500 (2013)
 9. Khamesipour F., Rahimi E., Shakerian A., Doosti A., Momtaz H.: 
Molecular study of the prevalence of Brucella abortus and Bru-
cella melitensis in the blood and lymph node samples of slaugh-
tered camels by polymerase chain reaction (PCR) in Iran. Acta 
Vet. Beog. 64, 245–256 (2014)
10. Roth F., Zinsstag J., Orkhon D., Chimed-Ochir G., Hutton G.: 
Human health benefits from livestock vaccination for brucel-
losis: case study. Bull. W. Health Organ. 81, 867–876 (2003)
11. FAO: Guidelines for coordinated human and animal brucellosis 
surveillance. FAO Animal Production and Health Paper 156, 
Rome, Italy, pp. 1–45. (2003)
BRUCELLOSIS: CURRENT STATUS OF THE DISEASE AND FUTURE PERSPECTIVES 343
12. Corbel M.J., MacMillan AP.: Brucellosis, Chapter 41. Volume III. 
In: Topley and Wilson’s, Microbiology and microbial infec- 
tions, 9th ed.; Hausler W.J., Sussman M., eds. Arnold, London 
(1999)
13. Baily G.G., Krahn L.B., Drasar B.S., Stoker N.G.: Detection of 
Brucella melitensis and Brucella abortus by DNA amplification. 
J. Trop. Med. Hyg. 95, 271–275 (1992)
14. Ghassan M., Issam A.K., Alex M.A.: Rapid laboratory confirma-
tion of human brucellosis by PCR analysis of a target sequence 
on the 31-kilodalton Brucella antigen DNA. J. Clin. Micro. 
477–478 (1996)
15. Sabir J., Mutawakil M., EL-Hanafy A., Al-Hejin A., Sadek M.A., 
Abou Alsoud M., Qureshi M., Saini K., Ahmed M.M.: Apply-
ing molecular tools for improving livestock performance: From 
DNA markers to next generation sequencing technologies. 
J. Food Agr. & Env. JFAE., 12, 541–553 (2014)
16. Ageely H., Bani I., Gaffar A.: Prevalence and risk factors for 
Brucellosis in Jazan province, Saudi Arabia. Trop. J. Pharm. Res. 
15, 189–194 (2016) 
17. Bansal Y., Aggarwal A., Gadepalli R., Nag V.L.: Seroprevalence 
of brucellosis in Western Rajasthan: A Study from a Tertiary 
Care Centre, Wolters Kluwer – Medknow, 30, 226–230 (2020)
18. Deka R.P., Magnusson U., Grace D., Lindahl J.: Bovine brucel-
losis: Prevalence, risk factors, economic cost and control options 
with eference to India – A review. Infect. Ecol. Epidemiol. 8, 
1556548 (2018)
19. Shome R., Kalleshamurthy T. et al.: Prevalence and risk fac-
tors of brucellosis among veterinary health care professionals. 
Pathog, Glob Health 111, 234–239 (2017)
20. Patil D.P., Ajjantha G.S. et al.: Trend of human brucellosis over 
a  decade at tertiary care centre in North Karnataka. Indian 
J. Med. Microbiol. 34, 427–432 (2016)
21. Mani S.S., Gunasekaran K.: Clinical spectrum, susceptibility 
profile, treatment and outcome of culture-confirmed brucel-
losis from South India. Indian J. Med. Microbiol. 36, 289–292. 
(2018)
22. Fallatah S.M., Oduloju J.S., Al-Dusari N.S., Fakunle M.Y.: 
Human brucellosis in Northern Saudi Arabia. Saudi. Med. J. 26, 
1562–1566 (2005)
23. Elfaki M.G., Alaidan A.A., Al-Hokail A.A.: Host response to 
Brucella infection: review and future prespective. J. Infect. Dev. 
Ctr. 9, 697–701 (2015)
24. Memish Z., Mah M.W.: Brucellosis in laboratory workers at 
a Saudi Arabian hospital. Am. J. Infect. Control. 29, 48–52 (2001)
25. Cooper C.W.: Risk factors in transmission of brucellosis from 
animals to humans in Saudi Arabia. Trans R. Soc. Trop. Med. 
Hyg. 86, 206–209 (1992)
26. Malik A.m.A.: Clinical Study of Brucellosis in Adults in the Asir 
Region of Southern Saudi Arabia. J. Trop. Med. Hyg. 6, 375–377 
(1997)
27. Kiel F.W., Khan M.Y.: Brucellosis in Saudi Arabia. Soc. Sci. Med. 
29, 999–1001 (1989)
28. Al Sekait M.A.: Seroepidemiological survey of brucellosis anti-
bodies in Saudi Arabia. Ann. Saudi Med. 19, 219–222 (1999)
29. Morgan W.J.B., Mackinnon D.J., Lawson J.R., Cullen G.A.: The 
rose bengal plate agglutination test in the diagnosis of brucel-
losis. Vet. Rec. 85, 636–641 (1969)
30. Halling S.M., Peterson-Burch B.D., Bricker B.J., Zuerner R.L., 
Qing Z., Li L.L., Kapur V., Alt D.P., Olsen S.C.: Completion of 
the genome sequence of Brucella abortus and comparison to the 
highly similar genomes of Brucella melitensis and Brucella suis. 
J. Bacteriol. 187, 2715–2726 (2005)
31. Pappas G., Papadimitriou P., Akritidi N., Christou L., Tsia-
nos E.V. The new global map of human brucellosis. Lancet Infect. 
Dis. 6, 91–99 10 (2006)
32. World Health Organization (WHO): Brucellosis in humans and 
animals. Geneva, Switserland: WHO Press. (2006)
33. Alto G., Jones L., Angus R., Verger J.: Techniques for the bru-
cellosis laboratory. 1st edn. Tech. rep., Institut National de la 
Recherche Agronomique, Paris. Referred to in L’opez-Gñi and 
O’Callaghan, (2012)
34. Lindquist D., Chu M.C., Probert W.W.S.: Francisella and Bru-
cella. In: Manual of Clinical Microbiology, 9th ed., Murray P.R., 
Baron E.J.O., Jorgensen J.H., et al. (eds.), ASM Press, Washing-
ton, D.C. pp. 824. (2007)
35. Paulsen I.T., Seshadri R.: The Brucella suis genome reveal fun-
damental similarities between animal and plant pathogens and 
symbionts. Prot. of Nat. Acad. of Sci. USA, 99, 13148–13153 (2002)
36. Blasco J.M., Diaz R.: Brucella melitensis Rev-1 vaccine as a cause 
of human brucellosis. Lancet, 342, 805 (1993)
37. OIE: Bovine Brucellosis. In: Diagnostic technique manual of 
standards for diagnostic tests and vaccine 4th ed., Paris: Office 
International Des Epizooties, pp. 328–345. Seifert S.H., Tropical 
animal health. (2nd edn), Kluver Academic Publishers, London, 
UK (2000)
38. Ragan V.E: The Animal and Plant Health Inspection Service 
(APHIS) brucellosis eradication program in the United States. 
Vet. Microbiol. 90, 11–18 (2002)
39. Blasco J.M., Molina-Flores B.: Control and eradication of bru-
cellosis. veterinary clinics of North America: F. Ani. Med. 27, 
95–104 (2011)
40. Lucero N.E., Ayala S.M., Escobar G.L., Jacob N.R.: Brucella iso-
lated in humans and animals in Latin America from 1968 to 
2006. Epid. Inf. 136, 496–503 (2008)
41. Godfroid J., Scholz C.H., et al.: Brucellosis at the animal/eco-
system/human interface at the beginning of the 21st century. 
Prev. Vet. Med. 102, 118–131 (2011)
42. McDermont J.J., Arimi S.M.: Brucellosis in sub-Saharan Africa: 
epidemiology, control and impact. Vet. Microbiol. 20, 111–134 
(2002)
43. Radostits O.M., Gay C.C., Hinchcliff K.W., Constable P.D.: 
Diseases associated with Brucella species. Veterinary Medi-
cine: A  textbook of the diseases of cattle, horses, sheep, pigs 
and goats. Elsevier Limited. Ragan, V.E., The Animal and Plant 
Health Inspection, 2007
44. Omer M.K., Skjerve E, Holstad G., Woldehiwet Z., Macmil-
lan  A.P.: Prevalence of antibodies to Brucella spp. in cattle, 
sheep,goats horses and camels in the state of Eritrea; Influence 
of husbandry system. Epid. Inf. 125, 447–455 (2000)
45. Bekele W.A., Tessema T.S., Melaku, S.K.: Camelus dromedarius 
brucellosis and its public health associated risks in the Afar 
National Regional State in north eastern Ethiopia. Acta Vet. 
Scand. 5, 1–8 (2013)
46. Tuli G.: Seroprevalence of Brucellosis in Cattle Slaughterd at 
Debre Zeit Elfora and Municipality Abattoirs and Evaluation 
of the Risk of Infection Abattoir Workers. Addis Ababa: Msc 
Thesis, Addis Ababa University, Akililu Lemma Institute of 
Pathobiology, 2009
47. Makita K., Fevre M.E., Waiswa C., Kaboyo W., De Clare Bron-
svoort M.B., Eisler C.M., Welburn C.S.: Human brucellosis 
in urban and peri-urban areas of Kampala, Uganda. Ann. N.Y. 
Acad. Sci. 1149, 309–311 (2008)
48. Bishop G.C., Bosman P.P., Herr S.: Bovine brucellosis: in infec-
tious diseases of livestock with special reference to Southern 
Africa. Edited by J.A.W Coetzer G.R, Thomson and R.C Tustin, 
Oxford University Press UK, p. 1053–1066, 1994
49. Ariza J., Gudiol F., Pallares R.: Treatment of human brucellosis 
with doxycycline plus rifampin or doxycycline plus strepto-
mycin: a randomized, double blind study. Ann. Intern. Med. 
117, 25–30 (1992)
344 SULAIMAN MOHAMMED ABU SULAYMAN, ROOP SINGH BORA, JAMAL S.M. SABIR MOHAMED MORSI M. AHMED
50. Swai E.S., Moshy W., Mbise E., Lutatina J. and Bwanga S.: 
Disease and health conditions affecting camel production in 
pastoral and agro-pastoral communities of northern Tanzania. 
Res. Opinion. Anim. Vety. Sci. 1, 83– 88 (2011)
51. Kubuafor D.K., Awumbila B., Akanmori B.D.: Seroprevalence of 
brucellosis in cattle and humans in the Akwapim-South district 
of Ghana: public health implications. Acta Trop. 76, 45–48 (2000)
52. Abram S.B.: Control of communicable diseases in man. 14th Ed. 
American Public Health Association, Washington. pp. 453, 1985
53. Benjamin B., Annobil S.H.: Childhood brucellosis in south-
western Saudi Arabia: A 5-year experience. J. Trop. Ped. 38, 
167–172 (1992)
54. Lulu A.R., Araj G.F., Khateeb M.I., Mustafa M.Y., Yusufu A.R., 
Fenech F.F.: Human brucellosis in Kuwait: A prospective study 
of 400 cases. Quarterly J. Med. 66, 39–54 (1988)
55. Schussler J.M., Fenves, A.Z., sutker W.L.: Intermittent fever 
and pancytopenia in a young Mexican man. South. Med. J. 10, 
1037–1039 (1997)
56. WHO: The development of new/Improved brucellosis vaccines 
Report of a WHO meeting. Geneva, Switzerland 11–12 Dec 
1997 (1998)
57. Yamout B.I., Nassar N.T., Ghayad E., Habdi A.: Neurobrucel-
losis, presentation, treatment and outcome in seven cases. Medit. 
J. Inf. Par. Dis. 11, 111–115 (1996)
58. Pouillot R., Garin-Bastuji B., Gerbier G., Coche Y., Cau C., 
Dufour B., Moutou F.: The brucellin skin test: A tool to discrimi-
nate false positive serological reaction in bovine brucellosis. Vet. 
Res. 28, 365–374 (1997)
59. Abdel-Hafeez M.M., Abdel-Kadder H.A., Bastawros A.F., 
EI-Ballal S.S., Hamdy M.E.R.: Bacteriological and pathological 
studies on Brucella melitensis infection in a dairy farm. Proceed-
ings of the Third Scientific Congress of the Egyptian Society for 
Cattle Diseases. Assuit, Egypt, 2, 266–274 (1995)
60. Fuerst R.: Microbiology i health and diseases 15th ed. W.B. Saun-
ders Co. London, pp. 669, 1983
61. Mohan K., Mkaya P.V., Muvavarirwa P., Matope G., Mahembe E., 
Pawandiwa  A.: Brucellosis surveillance and control in Zim-
babwe: bacteriological and serological investigation in dairy 
herds. J. Vet. Res. 63, 47–51 (1996)
62. Orner M.K., Skjerve E., MacMillan A.P., Woldehiwet Z.: Com-
parison of three serological tests in the diagnosis of Brucella 
infection in unvaccinated cattle in Eritrea. Pre. Vet. Med. 48, 
215–222 (2001)
63. Vanzini V.R., Aguirre N.P., Valentini B.S., Torioni de Echaide S., 
Lugaresi C.I., Marchesino M.D., Nielsen K.: Comparison of an 
indirect ELISA with the Brucella milk ring test for detection of 
antibodies to Brucella abortus in bulk milk samples. Vet. Micro-
biol. 82, 5–60 (2001)
64. Orner M.K., Skjerve E., Woldehiwet Z., Holstad G.: Risk factors 
for Brucella spp. infection in dairy cattle farms in Asmara, State 
of Eritrea. Prev. Vet. Med. 46, 257–265 (2000)
65. Queipo-Ortuno M.l., Morata P., Dcon P., Manchado P., Colme-
nero D.J.: Rapid diagnosis of Human brucellosis by peripheral 
blood PCR assay. J. Cli. Microb. 35, 2929–2930 (1997)
66. Tenover  F.C.: Diagnostic Deoxyribonucleic acid probes for 
infectious diseases. Clin. Microb. Rev. 1, 82–101 (1988)
67. Bricker B.J., Halling S.M.: Differentiation of Brucella abortus bv. 
1, 2 and 4, Brucella melitensis, Brucella ovis, and Brucella suis bv. 
1 by PCR. J. Clin. Microbiol. 32, 2660–2666 (1994)
68. Bricker B.J., Ewalt D.R., Olsen S.C., Jensen A.E.: Evaluation of 
the Brucella abortus species-specific polymerase chain reac- 
tion assay, an improved version of the Brucella AMOS polymer-
ase chain reaction assay for cattle. J. Vet. Diag. Inv. 15, 374–378 
(2003)
69. Banai M.: Control of small ruminant brucellosis by use of 
Brucella melitensis Rev. 1 vaccine: laboratory aspects and field 
observations. Vet. Microbiol. 90, 497–519 (2002) 
70. Smits H.L., Abdoel T.H., Solera J., Clavijo E., Diaz R.: Immu-
nochromatographic Brucella-specific immunoglobulin M and 
G lateral flow assays for rapid serodiagnosis of human brucel-
losis. Clin. Diag. Lab. Immun. 10, 1141–1146 (2003)
71. Blasco J.M., Diaz R.: Brucella melitensis Rev-1 vaccine as a cause 
of human brucellosis. Lancet, 342, 805 (1993)
72. Nicoletti P.V.: In Animal brucellosis. Edited by Nielsen K., Dun-
can J.R Boca Raton, Florida. CRC Press. pp. 283–299 (1990)
73. Blasco J.M.: A review of the use of B. melitensis Rev 1 vaccine in 
adult sheep and goats. Prev. Vet. Med. 31, 275–283 (1997) 
74. Fero E., Juma A., Koni A., Boci J., Kirandjiski T., Connor R., 
Wareth G., Koleci X.: The seroprevalence of brucellosis and 
molecular characterization of Brucella species circulating in the 
beef cattle herds in Albania. PLOS ONE, 5, pp. 1–14, 2020
75. Bundle D.R., McGiven J.: Brucellosis Improved diagnostics 
and vaccine insights from synthetic glycans. Acc. Chem. Res. 
50, 2958–2967 (2017)
76. Scholz H.C., Revilla-Fernandez S., et al.: Brucella vulpis sp. nov., 
isolated from mandibular lymph nodes of red foxes (Vulpes 
vulpes). Inter. J. Sys. Evo. Micro. 66, 2090–2098 (2016)
77. Lemos T.S, Cequinel J.C., et al.: Outbreak of human brucellosis 
in Southern Brazil and historical review of data from 2009 to 
2018. PLoS Neglected Trop. Dis. 12, e0006770 (2018)
